Related references
Note: Only part of the references are listed.Triple-Negative Breast Cancer Role of Specific Chemotherapy Agents
Steven J. Isakoff
CANCER JOURNAL (2010)
Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features
Ramachandran Venkitaraman
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
PARP-3 Is a Mono-ADP-ribosylase That Activates PARP-1 in the Absence of DNA
Olga Loseva et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic
Dana V. Ferraris
JOURNAL OF MEDICINAL CHEMISTRY (2010)
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
Chris T. Williamson et al.
MOLECULAR CANCER THERAPEUTICS (2010)
PARP inhibition: PARP1 and beyond
Michele Rouleau et al.
NATURE REVIEWS CANCER (2010)
Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post-ischaemic brain damage
F. Moroni et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin
Trevor Hay et al.
CANCER RESEARCH (2009)
Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity
Davide Melisi et al.
CLINICAL CANCER RESEARCH (2009)
The Importance of NAD in Multiple Sclerosis
W. Todd Penberthy et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications
Yvette Drew et al.
DRUG RESISTANCE UPDATES (2009)
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Ana M. Mendes-Pereira et al.
EMBO MOLECULAR MEDICINE (2009)
Development of PARP inhibitors in oncology
Jordi Rodon et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
Gianluca Papeo et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination
Isabelle Robert et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Structural Basis for Inhibitor Specificity in Human Poly(ADP-ribose) Polymerase-3
Lari Lehtio et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
PARP Inhibitors: Will the New Class of Drugs Match the Hype?
Rabiya S. Tuma
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
Shih-Min A. Huang et al.
NATURE (2009)
Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer
Baozhi Chen et al.
NATURE CHEMICAL BIOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
Elizabeth M. Swisher et al.
CANCER RESEARCH (2008)
Wnt/β-catenin signaling:: new (and old) players and new insights
He Huang et al.
CURRENT OPINION IN CELL BIOLOGY (2008)
Substrate-Assisted Catalysis by PARP10 Limits Its Activity to Mono-ADP-Ribosylation
Henning Kleine et al.
MOLECULAR CELL (2008)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Wataru Sakai et al.
NATURE (2008)
Tankyrase 1 and Tankyrase 2 Are Essential but Redundant for Mouse Embryonic Development
Y. Jeffrey Chiang et al.
PLOS ONE (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Toward specific functions of poly(ADP-ribose) polymerase-2
Jose Yelamos et al.
TRENDS IN MOLECULAR MEDICINE (2008)
DNA repair pathways as targets for cancer therapy
Thomas Helleday et al.
NATURE REVIEWS CANCER (2008)
The role of the poly(ADP-ribose) polymerase tankyrase1 in telomere length control by the TRF1 component of the shelterin complex
Jill R. Donigian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives
Zhenping Zhu
ACTA PHARMACOLOGICA SINICA (2007)
PARP-2 deficiency affects the survival of CD4+CD8+ double-positive thymocytes
Jose Yelamos et al.
EMBO JOURNAL (2006)
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
Nuala McCabe et al.
CANCER RESEARCH (2006)
Poly(ADP-ribose):: novel functions for an old molecule
Valerie Schreiber et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Emerging cancer therapeutic opportunities target DNA-repair systems
Jian Ding et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2006)
Molecular basis of ataxia telangiectasia and related diseases
LG Ball et al.
ACTA PHARMACOLOGICA SINICA (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Resolution of sister telomere association is required for progression through mitosis
JN Dynek et al.
SCIENCE (2004)
Alkylation damage in DNA and RNA -: repair mechanisms and medical significance
F Drablos et al.
DNA REPAIR (2004)
Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2
AW Oliver et al.
NUCLEIC ACIDS RESEARCH (2004)
A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage
SF El-Khamisy et al.
NUCLEIC ACIDS RESEARCH (2003)
TRF1 is degraded by ubiquitin-mediated proteolysis after release from telomeres
W Chang et al.
GENES & DEVELOPMENT (2003)
Poly(ADP-ribose) polymerase 2 localizes to mammalian active centromeres and interacts with PARP-1, Cenpa, Cenpb and Bub3, but not Cenpc
A Saxena et al.
HUMAN MOLECULAR GENETICS (2002)
Centromere proteins Cenpa, Cenpb, and Bub3 interact with poly(ADP-ribose) polymerase-1 protein and are poly(ADP-ribosyl)ated
A Saxena et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1
V Schreiber et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Targeting assay to study the cis functions of human telomeric proteins:: Evidence for inhibition of telomerase by TRF1 and for activation of telomere degradation by TRF2
K Ancelin et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease
PI Bauer et al.
BIOCHEMICAL PHARMACOLOGY (2002)
Role for the related poly(ADP-ribose) polymerases tankyrase 1 and 2 at human telomeres
BD Cook et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
TANK2, a new TRF1-associated poly(ADP-ribose) polymerase, causes rapid induction of cell death upon overexpression
PG Kaminker et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer
PL Welcsh et al.
HUMAN MOLECULAR GENETICS (2001)
Tankyrase promotes telomere elongation in human cells
S Smith et al.
CURRENT BIOLOGY (2000)
Share Paper
